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Objectives: Oral contraceptives (OCP) are highly effective, safe and widely used. Higher exposure to endogenous 
and exogenous estrogens is generally thought to increase the risk of breast cancer. Therefore, this study was con-
ducted to determine if oral contraceptive use affected the expression of CA 15-3, CEA and C-erb B-2 in the saliva 
of healthy women. 
Study design: The participants consisted of 87 healthy women (43 controls and 44 using oral contraceptives) rang-
ing in age from 20 to 54 years. The volunteers participated by giving one – time stimulated whole saliva samples. 
Then the samples were analysed for CA 15-3, CEA and C-erb B-2 concentrations. 
Results: The student t-test was used to compare group means for variables with comparable variability. The mean 
of C-erb B-2, CEA, and CA 15-3 concentrations (in the case and control groups) was (1.93, 1.70), (34.46, 31.62) and 
(12.58, 16.19) respectively. These differences were not statistically significant. 
Conclusions: Our findings suggest that the levels of the cancer biomarkers C-erb B-2, CEA and CA 15-3 were not 
affected by increased levels of estrogens in the body.
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Introduction
Oral contraceptives (OCP) are highly effective, safe 
and widely used, as 80% of all 35 years old women use 
or have used OCP in their lifetime. Side effects are the 
most common reported reason why women discontinue 
using OCP (1, 2). There is considerable evidence that 
the hormone replacement therapy is more strongly asso-
ciated with the risk of some invasive breast carcinomas 
(3). The incidence of breast cancer in 2007 may have 
decreased from previous decades but among women 
worldwide breast cancer is the most common cause of 
cancer death (4, 5). Attention to breast cancer screening, 
risk assessment and risk reduction strategies is neces-
sary to eradicate breast cancer and the deaths it causes 
(4). Saliva plays an important role in the protection of 
oral cavity and alterations in either salivary flow rate or 
protein composition may have dramatic effects on oral 
health. Diagnosis of diseases via the analysis of saliva is 
doi:10.4317/medoral.16.e29
http://dx.doi.org/doi:10.4317/medoral.16.e29
Med Oral Patol Oral Cir Bucal. 2011 Jan 1;16 (1):e29-32.                                                                                                                                             Oral contraceptive use and salivary biomarkers
e30
potentially valuable since collection of the saliva is as-
sociated with fewer compliance problems as compared 
with the collection of blood samples (5).  Three biomark-
ers that have been reported to be linked with breast can-
cer are C-erbB-2, CEA and CA15-3. C-erbB-2 (Her2/
neu) is a proto-oncogen localized to chromosome 17q 
and encodes a transmembrane tyrosine kinase growth 
factor receptor. The over expression of Her2/neu has 
been associated with breast, colorectal and head and 
neck cancers (6, 7). The soluble C-erbB-2 receptor pro-
tein levels have been detected in serum, nipple aspirates 
and saliva (7).   It has been reported that the assay of 
salivary C-erbB-2 protein is reliable and might have po-
tential use in the initial detection and follow up screen-
ing of breast cancer (8). CA15-3, a high-molecular-mass 
mucin-like glycoprotein, is expressed at the luminal 
surface of most secretary epithelial (9). This marker 
has been added to the recommendations of American 
Society of Clinical Oncology for use in tumor marker 
test panels (2). Currently the main clinical application 
of CA15-3 is for monitoring the patients with diagnosed 
breast carcinoma and preclinically detecting recur-
rences (7). It was also shown that the levels of circulat-
ing CA15-3 correlated with tumor size, thus reflecting 
disease stage (9). Carcinoembryonic antigen (CEA) is a 
glycoprotein that has been evaluated in a wide range of 
malignancies, including breast cancer and its levels may 
reflect the status of disease progression or regression. 
Although it has been noted that CEA is less sensitive 
than CA15-3, it may be useful in an early diagnosis of 
recurrences and monitoring response to treatment (10). 
It has been suggested that these markers might have the 
potential for use in initial detection and or follow up 
screening for the detection of breast cancer in women 
(11). Consequently, the use of saliva as an adjunct diag-
nostic fluid has merit for further study. So the purpose 
of the present study was to characterize the presence 
of salivary C-erbB-2, CEA and CA15-3 among healthy 
women who use OCP to address it, as a potential con-
founding variable in breast carcinomas.
Materials and Methods
The participants in the present study consisted of 87 
healthy women referred to the birth control center of 
Fatemyeh Hospital of Hamadan (the west of Iran) Uni-
versity of Medical Sciences from August 2008 to Au-
gust 2009. The subjects were socioeconomically mixed 
and ranged in age from 20 to 54 years. All participants 
signed a standard informed consent form approved by 
institutional review board. A detailed questionnaire was 
filled out for each participant regarding her past medical 
history. All subjects were in good general health and 
were not taking any prescribed or over the counter med-
ications (except OCP) during the course of the study. 
Furthermore, all subjects were premenopausal married 
women with normal flow and without any periods of 
amenorrhea. Height and weight were determined for all 
the subjects and then the mean body mass index (BMI) 
was calculated for each individual (BMI= weight/
[height]2 ). Two groups of women were selected: 1) The 
Case subjects who currently taking contraceptive tab-
lets (LD tablets at ordinary dose) at least for one year. 2) 
Those not using any type of hormonal birth control de-
fined as control subjects. Those subjects who have well 
confirmed risk factors for breast cancer were excluded 
from the study. These included: Family history in first 
and second degree relatives, age at first birth >30 or <20 
years, current breast feeding, history of ionizing radia-
tion and chemotherapy, menarche at <12 or >14 years, 
current smokers and alcohol consumption. Endogenous 
estrogen level was ignored. Two groups were matched 
regarding variables age, number of children, total time 
of breast feeding and BMI. Whole stimulated saliva 
was collected by standard method (12). All sample col-
lections were done between 9:00 AM and 11:00 AM. 
Subjects were instructed not to drink, eat, smoke and 
perform oral hygiene procedures for 90 minutes before 
saliva collection. A standard weighted cube of paraffin 
gum was used by asking the person to chew at a regular 
rate and expectorate into a collection glass tube every 
one minute for a total of 5 minutes. Then the saliva 
samples were frozen at -70 ˚C till further analysis. After 
collection of all samples, the saliva was analyzed for ex-
pression of biomarkers as follows: 1) C-erbB-2 concen-
tration was determined using ELISA kit (Bender Med 
Systems GmbH, Vienna, Austria) and expressed as ng/
ml.  2) CEA levels were assayed by ELISA kit (Pishtaz 
Teb Diagnostics, Tehran, Iran) and expressed as ng/ml. 
3) CA15-3 concentrations were analyzed using EIA kit 
(CanAg, Gothenburg, Sweden) and expressed as Units/
ml. Biomarkers assaying was performed as recom-
mended detailed procedures by the own manufacturers. 
Statistical analysis was performed by student’s t-test us-
ing SPSS software package (version 13), with α level 
< 0.05 considered as statistically significant.
Results
From 87 women participated in this study, 44 subjects 
were in the OCP user (Case) group and 43 in the control 
group. As mentioned above, some confounding vari-
ables were matched between the studied groups. 
So there were no significant differences between the 
case and control subjects regarding age, number of chil-
dren, total time of breast feeding and BMI (Table 1). 
The salivary levels of C-erbB-2, CEA and CA15-3 
among women with OCP exposure and their control 
group are shown in table 2. The data demonstrated that 
there were no significant differences between the two 
groups in the expression of these biomarkers.
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Discussion
Different studies have defined the risk of breast cancer 
by evaluation of tumor markers expression and the use 
of OCP; nevertheless some have reported no significant 
correlation (13-15). Overall, there is a mutual agreement 
on the usefulness of tumor markers (e.g. C-erbB-2, CEA 
and CA15-3) for the prognosis of breast cancer (16-18). In 
the present study, all participants were similar according 
to the marital status, menstrual cycle, menopause status, 
onset of menarche and the age of first birth. Also, vari-
ables age, number of children, total time of breast feed-
ing and BMI were matched between OCP and non-OCP 
users.  A cohort study among healthy women showed 
no association between variables age, race, tobacco us-
age, menopausal status, estrogen use, systemic diseas-
es, prescription medications and salivary C-erbB-2 and 
CA15-3 (11). Streckfus et al.  (8) suggested that the assay 
of salivary C-erbB-2 is reliable and might have potential 
use in the initial detection and follow up screening for 
breast cancer. The two aforementioned studies have uti-
lized stimulated saliva and ELISA method for assaying 
of tumor markers among healthy women. The results of 
the present study indicated that there were no statisti-
cal differences between OCP users and the controls in 
the salivary expression of biomarkers. McIntyre et al . 
(2) have analyzed stimulated whole saliva samples of 
40 healthy women (OCP and non-OCP users) regard-
ing the expression of C-erbB-2 and CA15-3 using im-
muno assaying method. They selected premenopausal 
women with normal menstrual cycle and finally found 
no significant differences between the control and study 
subjects. Moreover, they have noted that anti-estrogen 
therapy (e.g. tamoxifen) should not alter the expression 
of these biomarkers. Although the findings of McIntyre 
et al (2) and the present study are similar, the results of 
the present study are more clear and definite. In a review 
study by Hankinson  et al. (15) the well confirmed risk 
factors for breast cancer were as follow: Family history 
of breast cancer, increase of BMI, benign breast diseas-
es, not parity, age at first birth >30 or <20 years, no lac-
tation, menopause at >54 or <45 years, high endogenous 
estrogen levels, history of ionizing radiation exposure, 
menarche at <12 or >14 years and alcohol consumption. 
Approximately all mentioned risk factors were consid-
ered in the case and control groups of the present study. 
Furthermore, a larger sample size was analyzed based 
Table 1. Characteristics of women who used OCP and those without hormonal birth control.
OPC: Oral Contraceptives
BMI: Body Mass Index










Biomarkers                           OCP users (n=44)              Controls (n=43)               P. value 
                                                   Mean ± SD                       Mean ± SD                        
C-erb B-2 (ng/ml)                        1.93 ± 0.95                       1.70 ± 0.96                     0.26 
CA 15-3 (units/ml)                     12.58 ± 9.79                     16.19 ± 10.8                     0.44 
CEA (ng/ml)                               34.46 ± 17.41                   31.62 ± 17.24                   0.44 

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on the statistical reasons to find more obvious relation 
between OCP usage and the expression of tumor mark-
ers. The results of the present study demonstrated that 
the monitoring of women with high estrogen levels us-
ing salivary C-erbB-2, CEA and CA15-3 seems not to 
be useful, however further definitive studies are man-
datory. Interest in saliva even more increased with the 
finding that saliva is filled with hundreds of components 
that may serve to detect systemic diseases or evidence 
of exposure to various harmful substances, as well as 
provide biomarkers of health and disease status (19). In 
our study, saliva samples collection was done under the 
standard method defined by Navazesh (12). It has been 
noted; although saliva is potentially an attractive diag-
nostic fluid, standardization of the collection procedure 
is of ultimate importance in order to obtain reproduc-
ible results. Standardization of the conditions for collec-
tion of saliva is strictly essential for achieving reliability 
and interpretation of the data (20). Saliva as a diagnostic 
medium has many advantages over serum and many of 
the hazards associated with blood collection do not ap-
ply to saliva. It is a clear colorless fluid that its collection 
is easy and noninvasive and may be done repeatedly 
without discomfort to the patient. There is no need for 
sharps, which have the potential for cross contamina-
tion among patients when used improperly and present 
a danger to health care personnel. Because of the low 
concentrations of antigens in saliva, HIV and hepatitis 
infections are much less of a danger from saliva than 
from blood (2, 9, 11, 19). In summery; saliva could be a 
cost effective tool to monitor the health status, screen-
ing and diagnostic approaches.
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